# Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer

> **NCT03841136** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 70 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer

## Interventions

- **DRUG:** anlotinib

## Key facts

- **NCT ID:** NCT03841136
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-01
- **Primary completion:** 2019-12-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2019-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03841136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03841136, "Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03841136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*